Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

Nature Medicine

Volumn 22, Issue 3, 2016, Pages 288-297

  Schneider, Rebekka K ^a,b   Schenone, Monica ^c   Ferreira, Monica Ventura ^b   Kramann, Rafael ^a   Joyce, Cailin E ^d   Hartigan, Christina ^c   Beier, Fabian ^b   Brümmendorf, Tim H ^b   Germing, Ulrich ^e   Platzbecker, Uwe ^f   Büsche, Guntram ^g   Knüchel, Ruth ^b   Chen, Michelle C ^a   Waters, Christopher S ^a   Chen, Edwin ^a   Chu, Lisa P ^a   Novina, Carl D ^d   Lindsley, R Coleman ^a,d   Carr, Steven A ^b   Ebert, Benjamin L ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; PROTEIN P53; RIBOSOMAL PROTEIN SUBUNIT 14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; RIBOSOMAL PROTEIN S14; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ERYTHROBLAST; ERYTHROID CELL; GENE INACTIVATION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; ANEMIA; ANIMAL; BONE MARROW; CONFOCAL MICROSCOPY; DISEASE MODEL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IN VITRO STUDY; KNOCKOUT MOUSE; MASS SPECTROMETRY; MEGAKARYOCYTE; METABOLISM; MYELODYSPLASTIC SYNDROME; PATHOLOGY; WESTERN BLOTTING;

ANEMIA; ANIMALS; BLOTTING, WESTERN; BONE MARROW; CALGRANULIN A; CALGRANULIN B; CYTOKINES; DISEASE MODELS, ANIMAL; ERYTHROID PRECURSOR CELLS; ERYTHROPOIESIS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; IN VITRO TECHNIQUES; MASS SPECTROMETRY; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; MYELODYSPLASTIC SYNDROMES; RIBOSOMAL PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84958078801     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4047     Document Type: Article

References (60)

1. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 23, 1252-1256 (2009).
2. Ebert B.L. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin. Oncol. 38, 621-626 (2011).
3. Komrokji R.S, Padron E, Ebert B.L, & List A.F. Deletion 5q MDS: molecular and therapeutic implications. Best Pract. Res. Clin. Haematol. 26, 365-375 (2013).
4. Ebert B.L, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451, 335-339 (2008).
5. Choesmel V, et al. Impaired ribosome biogenesis in Diamond-Blackfan anemia. Blood 109, 1275-1283 (2007).
6. Ruggero D, & Shimamura A. Marrow failure: a window into ribosome biology. Blood 124, 2784-2792 (2014).
7. McGowan K.A, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat. Genet. 40, 963-970 (2008).
8. McGowan K.A, et al. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood 118, 3622-3633 (2011).
9. Matsson H, et al. Erythropoiesis in the Rps19-disrupted mouse: analysis of erythropoietin response and biochemical markers for Diamond-Blackfan anemia. Blood Cells Mol. Dis. 36, 259-264 (2006).
10. Dutt S, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 117, 2567-2576 (2011).
11. Pellagatti A, et al. Induction of p53 and upregulation of the p53 pathway in the human 5q- syndrome. Blood 115, 2721-2723 (2010).
12. Zhou X, Hao Q, Liao J, Zhang Q, & Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 32, 388-396 (2013).
13. Barlow J.L, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med. 16, 59-66 (2010).
14. Raiser D.M, Narla A, & Ebert B.L. The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders. Leuk. Lymphoma 55, 491-500 (2014).
15. Volarevic S, et al. Proliferation but not growth blocked by conditional deletion of 40S ribosomal protein S6. Science 288, 2045-2047 (2000).
16. Morrison S.J, Wandycz A.M, Akashi K, Globerson A, & Weissman I.L. The aging of hematopoietic stem cells. Nat. Med. 2, 1011-1016 (1996).
17. Pang W.W, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc. Natl. Acad. Sci. USA 108, 20012-20017 (2011).
18. Du W, et al. Inflammation-mediated notch signaling skews Fanconi anemia hematopoietic stem cell differentiation. J. Immunol. 191, 2806-2817 (2013).
19. Signer R.A, Magee J.A, Salic A, & Morrison S.J. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 509, 49-54 (2014).
20. Lajtha L.G, & Oliver R. A kinetic model of the erythron. Proc. R. Soc. Med. 54, 369-371 (1961).
21. Karbstein K. Inside the 40S ribosome assembly machinery. Curr. Opin. Chem. Biol. 15, 657-663 (2011).
22. Strunk B.S, & Karbstein K. Powering through ribosome assembly. RNA 15, 2083-2104 (2009).
23. Strunk B.S, et al. Ribosome assembly factors prevent premature translation initiation by 40S assembly intermediates. Science 333, 1449-1453 (2011).
24. Chen X, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J. Clin. Invest. 123, 4595-4611 (2013).
25. Starczynowski D.T, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 16, 49-58 (2010).
26. Bresnick A.R, Weber D.J, & Zimmer D.B. S100 proteins in cancer. Nat. Rev. Cancer 15, 96-109 (2015).
27. Li C, et al. A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem. J. 422, 363-372 (2009).
28. Tan M, Heizmann C.W, Guan K, Schafer B.W, & Sun Y. Transcriptional activation of the human S100A2 promoter by wild-Type p53. FEBS Lett. 445, 265-268 (1999).
29. Mueller A, et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J. Biol. Chem. 280, 29186-29193 (2005).
30. Hiratsuka S, Watanabe A, Aburatani H, & Maru Y. Tumor-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8, 1369-1375 (2006).
31. Bibikova E, et al. TNF-mediated inflammation represses GATA1 and activates p38 MAP kinase in RPS19-deficient hematopoietic progenitors. Blood 124, 3791-3798 (2014).
32. Schepers K, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285-299 (2013).
33. Kordasti S.Y, et al. IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low-risk myelodysplastic syndrome. Br. J. Haematol. 145, 64-72 (2009).
34. Su S, et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1? by interacting mainly with a C-C chemokine receptor, CCR1. Blood 90, 605-611 (1997).
35. Frisch B.J, et al. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119, 540-550 (2012).
36. Vogl T, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat. Med. 13, 1042-1049 (2007).
37. Ehrchen J.M, Sunderkötter C, Foell D, Vogl T, & Roth J. The endogenous Toll-like receptor 4 agonist S100A8-S100A9 (calprotectin) as an innate amplifier of infection, autoimmunity and cancer. J. Leukoc. Biol. 86, 557-566 (2009).
38. Wei Y, et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia 27, 2177-2186 (2013).
39. Chang K.H, et al. p62 is required for stem cell-progenitor retention through inhibition of IKK-NF-?B-Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Rep. 9, 2084-2097 (2014).
40. Starczynowski D.T, & Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 9, 855-856 (2010).
41. Starczynowski D.T, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-?B pathways in human lung cancer. J. Clin. Invest. 121, 4095-4105 (2011).
42. Reynaud D, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661-673 (2011).
43. Rhyasen G.W, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90-104 (2013).
44. Kristinsson S.Y, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J. Clin. Oncol. 29, 2897-2903 (2011).
45. Takizawa H, Boettcher S, & Manz M.G. Demand-Adapted regulation of early hematopoiesis in infection and inflammation. Blood 119, 2991-3002 (2012).
46. Verschoor C.P, et al. Blood CD33+HLA-DR? myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 93, 633-637 (2013).
47. Raaijmakers M.H, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852-857 (2010).
48. Fang J, et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome-Acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 120, 858-867 (2012).
49. Rossi D.J, et al. Deficiencies in DNA damage repair limit the function of hematopoietic stem cells with age. Nature 447, 725-729 (2007).
50. Means R.T. Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 13, 32-37 (1995).
51. Sawanobori M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk. Res. 27, 583-591 (2003).
52. Jacobs-Helber S.M, et al. Tumor necrosis factor-Alpha expressed constitutively in erythroid cells or induced by erythropoietin has negative and stimulatory roles in normal erythropoiesis and erythroleukemia. Blood 101, 524-531 (2003).
53. Sahin E, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011).
54. Schneider R.K, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509-520 (2014).
55. Shuga J, Zhang J, Samson L.D, Lodish H.F, & Griffith L.G. In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds. Proc. Natl. Acad. Sci. USA 104, 8737-8742 (2007).
56. Gritsman K, et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110-?. J. Clin. Invest. 124, 1794-1809 (2014).
57. Mertins P, et al. Integrated proteomic analysis of post-Translational modifications by serial enrichment. Nat. Methods 10, 634-637 (2013).
58. Rappsilber J, & Mann M. Analysis of the topology of protein complexes using cross-linking and mass spectrometry. Cold Spring Harb. Protoc. doi: 10.1101/pdb.prot4594 (2007).
59. Beier F, et al. Telomere-length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus using multicolor flow-FISH. Lupus 16, 955-962 (2007).
60. Beier F, et al. Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. Blood 106, 531-533 (2005).